OrthoPediatrics (KIDS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - OrthoPediatrics reported revenue of $61.61 million for the quarter ended December 2025, marking a year-over-year increase of 17% and exceeding the Zacks Consensus Estimate by 4.05% [1] - The company’s EPS for the same period was -$0.26, an improvement from -$0.29 a year ago, with a surprise of 29.73% compared to the consensus estimate of -$0.37 [1] Revenue Performance - Product sales in the Trauma and deformity category reached $42.64 million, slightly below the estimated $43.45 million, but still reflecting a year-over-year increase of 17.1% [4] - Sales in the Sports medicine/other category were reported at $1.37 million, significantly surpassing the average estimate of $0.68 million, representing a remarkable year-over-year growth of 118.5% [4] - Scoliosis product sales amounted to $17.6 million, exceeding the estimated $15.17 million, with a year-over-year increase of 12.6% [4] Stock Performance - Over the past month, OrthoPediatrics shares have returned -3.5%, contrasting with the Zacks S&P 500 composite's increase of +0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]